Pruritus In Hemodialysis Therapeutics
1. Korsuva patent expiration
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10793596 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US7727963 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US10017536 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US8536131 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US7713937 | VIFOR INTL | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US7402564 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10138270 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US8486894 | VIFOR INTL | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US8217007 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US9334305 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 10 months from now) | |
| US9359399 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| US8236766 | VIFOR INTL | Uses of synthetic peptide amides |
Nov, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 23 August, 2025
Market Authorisation Date: 23 August, 2021
Dosage: SOLUTION
More Information on Dosage
KORSUVA family patents
